Published on Monday June 05, 2017
Smooth Drug Development May 2017 News Release
New clinical trials activities were initiated at Smooth Drug Development:
- We signed an agreement to conduct a I phase clinical study;
- We signed an agreement for the preparation of literature review for phase II and III clinical studies;
- We were awarded with three bioequivalence studies;
- We were awarded with two projects for the preparation of medical documentation for bioequivalence studies;
- We signed an agreement for the preparation of medical documentation for II phase clinical study.
Our team reached new milestones in our ongoing clinical trials:
- We are ready to apply for a MoH clinical study approval of a bioequivalence study;
- We closed the database in a phase III clinical study in patients with erectile dysfunction;
- We enrolled 30% of patients in our ongoing phase III study in patients with erectile dysfunction. The enrollment is one month ahead of schedule;
- Our team is happy to announce that all patients were randomized in a phase III study with a vaginal delivery system;
- The enrollment is closed and the treatment phase was started in a phase III study with a vaginal delivery system;
- The enrollment was closed in a phase III study in patients with primary immunodeficiency. The enrollment is one month ahead of schedule.
Besides, the company is gearing up for the participation in DIA, BIO, ADA and ASCO exhibitions. Smooth Drug Development will have an exhibition booth #1258 at the DIA conference.